Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap
Pith reviewed 2026-05-25 01:13 UTC · model grok-4.3
The pith
Extending regression discontinuity to survival curves shows no evidence that generic immediate-release venlafaxine lacks therapeutic equivalence to the brand version.
A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.
Core claim
We define, identify under assumptions, and estimate using G-computation a causal effect for a time-to-event outcome by extending regression discontinuity to survival curves. Application to immediate-release venlafaxine in insurance claims data provides no evidence for a lack of therapeutic equivalence between brand and generic versions.
What carries the argument
Regression discontinuity design extended to survival curves with G-computation estimation, which identifies the causal effect at the point of generic drug availability while handling non-adherence and secular trends.
Load-bearing premise
The regression discontinuity assumptions hold at the time when the generic becomes available, including that potential outcomes are continuous across that threshold except for the treatment change.
What would settle it
A randomized trial showing a statistically significant difference in event rates between brand and generic users right after generic approval would falsify the no-difference conclusion.
read the original abstract
While generic drugs offer a cost-effective alternative to brand name drugs, regulators need a method to assess therapeutic equivalence in a post market setting. We develop such a method in the context of assessing the therapeutic equivalence of immediate release (IM) venlafaxine, based on a large insurance claims dataset provided by OptumLabs\textsuperscript{\textregistered}. To properly address this question, our methodology must deal with issues of non-adherence, secular trends in health outcomes, and lack of treatment overlap due to sharp uptake of the generic once it becomes available. We define, identify (under assumptions) and estimate (using G-computation) a causal effect for a time-to-event outcome by extending regression discontinuity to survival curves. We do not find evidence for a lack of therapeutic equivalence of brand and generic IM venlafaxine.
Editorial analysis
A structured set of objections, weighed in public.
Referee Report
Summary. The manuscript develops a causal method extending regression discontinuity designs to time-to-event outcomes via G-computation to evaluate post-market therapeutic equivalence of brand versus generic immediate-release venlafaxine. It addresses non-adherence, secular trends, and non-overlap using a large OptumLabs claims dataset and reports no evidence against equivalence.
Significance. If the identification strategy holds, the work supplies a practical observational approach for regulators to assess generic equivalence when RCTs are infeasible, leveraging the sharp policy cutoff at generic availability. The RD-plus-G-computation extension for survival curves could apply more broadly to other non-overlapping policy interventions with time-to-event endpoints.
major comments (1)
- [Abstract and Identification section] The identification assumptions required to extend RD to survival curves (continuity of conditional potential survival functions and hazards at the generic-availability cutoff, no other discontinuities in censoring or covariate processes, and correct specification of the G-computation outcome model) are invoked but never enumerated or subjected to validation (e.g., placebo tests or falsification checks). This is load-bearing for the central causal claim.
Simulated Author's Rebuttal
We thank the referee for the constructive feedback and for recognizing the potential significance of the work. We address the single major comment below and will revise the manuscript to incorporate the suggested improvements.
read point-by-point responses
-
Referee: [Abstract and Identification section] The identification assumptions required to extend RD to survival curves (continuity of conditional potential survival functions and hazards at the generic-availability cutoff, no other discontinuities in censoring or covariate processes, and correct specification of the G-computation outcome model) are invoked but never enumerated or subjected to validation (e.g., placebo tests or falsification checks). This is load-bearing for the central causal claim.
Authors: We agree that the assumptions should be enumerated explicitly rather than invoked in passing. In the revised manuscript we will add a dedicated subsection under Identification that lists the three core assumptions: (1) continuity of the conditional potential survival functions and hazards at the generic-availability cutoff, (2) no other discontinuities in censoring or covariate processes at the cutoff, and (3) correct specification of the G-computation outcome model. We will also expand the text to discuss the feasibility of falsification checks. Because the design relies on a single sharp policy cutoff, classical placebo tests at alternative cutoffs are not available; however, we will report sensitivity analyses that vary the bandwidth, the functional form of the outcome model, and the inclusion of additional covariates to probe robustness. These changes will be made without altering the empirical results or conclusions. revision: yes
Circularity Check
No circularity: derivation relies on standard external methods
full rationale
The provided abstract and description define and estimate a causal effect for time-to-event data by extending regression discontinuity designs to survival curves and applying G-computation, invoking (unspecified) identification assumptions. No equations, self-definitions, fitted inputs renamed as predictions, or load-bearing self-citations appear in the text. The central claim rests on external statistical tools and assumptions that are not shown to reduce to the paper's own inputs by construction, making the derivation self-contained against standard benchmarks.
Axiom & Free-Parameter Ledger
axioms (1)
- domain assumption Assumptions allowing identification of the causal effect using the extended regression discontinuity design for survival outcomes
discussion (0)
Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.